Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

1,800

Employees1,800

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

1,800

Employees1,800

NBIX Key Statistics

Market cap

14.09B

Market cap14.09B

Price-Earnings ratio

33.72

Price-Earnings ratio33.72

Dividend yield

—

Dividend yield—

Average volume

970.63K

Average volume970.63K

High today

$142.15

High today$142.15

Low today

$138.75

Low today$138.75

Open price

$138.75

Open price$138.75

Volume

1.13M

Volume1.13M

52 Week high

$160.18

52 Week high$160.18

52 Week low

$84.23

52 Week low$84.23

Stock Snapshot

With a market cap of 14.09B, Neurocrine(NBIX) trades at $141.20. The stock has a price-to-earnings ratio of 33.72.

On 2026-02-07, Neurocrine(NBIX) stock moved within a range of $138.75 to $142.15. With shares now at $141.20, the stock is trading +1.8% above its intraday low and -0.7% below the session's peak.

Trading activity shows a volume of 1.13M, compared to an average daily volume of 970.63K.

The stock's 52-week range extends from a low of $84.23 to a high of $160.18.

NBIX News

Simply Wall St 4h

Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation

Neurocrine Biosciences (NasdaqGS:NBIX) has started a Phase 2 clinical trial of its investigational compound NBI-1065890 for tardive dyskinesia. The company is...

Simply Wall St 5d

How Investors Are Reacting To Neurocrine Biosciences Launching Phase 2 Trial For Longer-Acting TD Drug

In late January 2026, Neurocrine Biosciences began a Phase 2 randomized, double-blind, placebo-controlled trial of its investigational VMAT2 inhibitor NBI-10658...

Simply Wall St 7d

Neurocrine Biosciences Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update

Advertisement Why this new trial matters for Neurocrine Biosciences (NBIX) shareholders Neurocrine Biosciences (NBIX) has kicked off a Phase 2 trial of NBI-10...

Analyst ratings

87%

of 30 ratings

Buy

86.7%

Hold

13.3%

Sell

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Procore Technologies

Alnylam Pharmaceuticals

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.